Hidemichi Kouzu

Dr. Hidemichi Kouzu

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2012 in Heart Failure Reviews
Verified
Journal Article
Open access
PDF file
TMTakayuki Miki
Takayuki Miki
SYSatoshi Yuda
Satoshi Yuda
HKHidemichi Kouzu
Hidemichi Kouzu
TMTetsuji Miura
Tetsuji Miura
Since diabetic cardiomyopathy was first reported four decades ago, substantial information on its pathogenesis and clinical features has accumulated. In the heart, diabetes enhances fatty acid metabolism, suppresses glucose oxidation, and modifies intracellular signaling, leading to impairments in multiple steps of excitation–contraction coupling, inefficient energy production, and increased susceptibility to ischemia/reperfusion injury. Loss of normal microvessels and remodeling of the extracellular matrix are also involved in contractile dysfunction of diabetic hearts. Use of sensitive echocardiographic techniques (tissue Doppler imaging and strain rate imaging) and magnetic resonance spectroscopy enables detection of diabetic cardiomyopathy at an early stage, and a combination of the modalities allows differentiation of this type of cardiomyopathy from other organic heart diseases. Circumstantial evidence to date indicates that diabetic cardiomyopathy is a common but frequently unrecognized pathological process in asymptomatic diabetic patients. However, a strategy for prevention or treatment of diabetic cardiomyopathy to improve its prognosis has not yet been established. Here, we review both basic and clinical studies on diabetic cardiomyopathy and summarize problems remaining to be solved for improving management of this type of cardiomyopathy.

1 February 2013 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
AMAtsushi Mochizuki
Atsushi Mochizuki
SYSatoshi Yuda
Satoshi Yuda
YOYukiko Oi
Yukiko Oi
MKMina Kawamukai
Mina Kawamukai
JNJunichi Nishida
Junichi Nishida
TMTetsuji Miura
Tetsuji Miura

1 February 2011 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
HKHidemichi Kouzu
Hidemichi Kouzu
SYSatoshi Yuda
Satoshi Yuda
AMAtsuko Muranaka
Atsuko Muranaka
TDTakahiro Doi
Takahiro Doi
HYHitomi Yamamoto
Hitomi Yamamoto
KSKazuaki Shimamoto
Kazuaki Shimamoto

1 October 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MTMasaya Tanno
Masaya Tanno
AKAtsushi Kuno
Atsushi Kuno
SISatoko Ishikawa
Satoko Ishikawa
TMTakayuki Miki
Takayuki Miki
HKHidemichi Kouzu
Hidemichi Kouzu
TMTetsuji Miura
Tetsuji Miura
Glycogen synthase kinase-3β (GSK-3β) is a major positive regulator of the mitochondrial permeability transition pore (mPTP), a principle trigger of cell death, under the condition of oxidative stress. However, the mechanism by which cytosolic GSK-3β translocates to mitochondria, promoting mPTP opening, remains unclear. Here we addressed this issue by analyses of the effect of site-directed mutations in GSK-3β on mitochondrial translocation and protein/protein interactions upon oxidative stress. H9c2 cardiomyoblasts were transfected with GFP-tagged GSK-3β (WT), a mutant GSK-3β insensitive to inhibitory phosphorylation (S9A), or kinase-deficient GSK-3β (K85R). Time lapse observation revealed that WT and S9A translocated from the cytosol to the mitochondria more promptly than did K85R after exposure to oxidative stress. H2O2 increased the density of nine spots on two-dimensional gel electrophoresis of anti-GSK-3β-immunoprecipitates by more than 3-fold. MALDI-TOF/MS analysis revealed that one of the spots contained voltage-dependent anion channel 2 (VDAC2). Knockdown of VDAC2, but not VDAC1 or VDAC3, by siRNA attenuated both the mitochondrial translocation of GSK-3β and mPTP opening under stress conditions. The mitochondrial translocation of GSK-3β was attenuated also when Lys-15, but not Arg-4 or Arg-6, in the N-terminal domain of GSK-3β was replaced with alanine. The oxidative stress-induced mitochondrial translocation of GSK-3β was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3β inhibitor. These results demonstrate that GSK-3β translocates from the cytosol to mitochondria in a kinase activity- and VDAC2-dependent manner in which an N-terminal domain of GSK-3β may function as a mitochondrial targeting sequence.

18 June 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TSTatsuya Sato
Tatsuya Sato
HCHsiang-Chun Chang
Hsiang-Chun Chang
MBMarina Bayeva
Marina Bayeva
JSJason S. Shapiro
Jason S. Shapiro
LRLucia Ramos-Alonso
Lucia Ramos-Alonso
HAHossein Ardehali
Hossein Ardehali
Cells respond to iron deficiency by activating iron-regulatory proteins to increase cellular iron uptake and availability. However, it is not clear how cells adapt to conditions when cellular iron uptake does not fully match iron demand. Here, we show that the mRNA-binding protein tristetraprolin (TTP) is induced by iron deficiency and degrades mRNAs of mitochondrial Fe/S-cluster-containing proteins, specifically Ndufs1 in complex I and Uqcrfs1 in complex III, to match the decrease in Fe/S-cluster availability. In the absence of TTP, Uqcrfs1 levels are not decreased in iron deficiency, resulting in nonfunctional complex III, electron leakage, and oxidative damage. Mice with deletion of Ttp display cardiac dysfunction with iron deficiency, demonstrating that TTP is necessary for maintaining cardiac function in the setting of low cellular iron. Altogether, our results describe a pathway that is activated in iron deficiency to regulate mitochondrial function to match the availability of Fe/S clusters. Significance Iron deficiency is the most common nutrient deficiency, yet cardiomyopathy rarely develops in these patients. We solved this paradox and identified a protective mechanism involving the mRNA-binding protein tristetraprolin (TTP), which adjusts mitochondrial function in response to iron deficiency. Mice lacking TTP in their hearts were phenotypically normal at baseline but developed spontaneous cardiomyopathy under iron deficiency and exhibited increased reactive oxygen species (ROS)-mediated damage in their hearts. We further demonstrate that down-regulation of specific iron-containing mitochondrial complexes by TTP is the mechanism preventing the formation of dysfunctional mitochondria, subsequent ROS production, and cellular damage. In summary, we show that activation of TTP is part of a required pathway protecting critical organ function when iron becomes scarce.

1 March 2009 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HKHidemichi Kouzu
Hidemichi Kouzu
SNSatoshi Nakatani
Satoshi Nakatani
SKShingo Kyotani
Shingo Kyotani
HKHideaki Kanzaki
Hideaki Kanzaki
NNNorifumi Nakanishi
Norifumi Nakanishi
MKMasafumi Kitakaze
Masafumi Kitakaze